Sorry, your browser does not support JavaScript!
Find a Treatment Center
Investor Relations
Contact Us
KiteKonnect®
About Us
Our Mission
Our Story
Therapeutic Areas
Leadership
Kite Locations
Science & Medicine
Our Technology
Our Therapies
Pipeline
Trials & Expanded Access
External Research Program (ERP)
Newsroom
Newsroom
Press Releases
Company Statements
Media Kit
Careers
Now Hiring
Careers at Kite
Manufacturing Careers at Kite
Early Talent Programs at Kite
Culture & Benefits
Utility
Contact Us
KiteKonnect®
BACK TO MAIN MENU
Company Statements
Kite Expands Cell Therapy Manufacturing Operations in Maryland
Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case
Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia
Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma
Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma
Kite Announces U.S. FDA Clearance of Investigational
Find a Treatment Center
Investor Relations
Toggle Inner Dropdown
BACK TO MAIN MENU
Google.com
Compliance Program
Gilead Ethics and Code of Conduct
US Disclosures
California
